Clinical trials: Bacterial Diseases
Cystic Fibrosis, Allergic Bronchopulmonary Aspergillosis
An Exploratory Study to Assess Multiple Doses of Omalizumab in Patients With Cystic Fibrosis Complicated by Acute Bronchopulmonary Aspergillosis (ABPA)
This study will evaluate the safety and efficacy of omalizumab for the treatment of Allergic Bronchopulmonary Aspergillosis (ABPA) in patients with Cystic Fibrosis aged 12 years and older.
- Trial name
- NCT00787917
- Testing
- Omalizumab, Itraconazole
- Where
- 10 sites in Belgium, Germany and 3 more
- Volunteers
- 14 people
- Sponsor
- Novartis Pharmaceuticals
Onychomycosis
A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-108 in Patients With Onychomycosis
The purpose of this study is to assess the safety and effectiveness of two concentrations of IDP-108 in treating patients with onychomycosis
- Trial name
- NCT00777868
- Testing
- Low Strength IDP-108, High Strength IDP-108, High Strength IDP-108 under occlusion
- Where
- 10 sites in Mexico
- Volunteers
- 135 people
- Sponsor
- Dow Pharmaceutical Sciences
Healthy
Study Evaluating the Safety and Ability to Produce Immune Response of Prevenar and Meningitec Given at the Same Time
The purpose of this study is to evaluate the safety and immunogenicity of concomitant Prevenar and Meningitec compared to Prevenar alone and Meningitec alone when used as part of the routine vaccination series in healthy infants
- Trial name
- NCT00581035
- Testing
- Prevenar and Meningitec, Prevenar, Meningitec
- Volunteers
- 712 people, healthy volunteers welcome
- Sponsor
- Wyeth is now a wholly owned subsidiary of Pfizer
Bacterial Infections
Expanded Access to Cefiderocol for the Intravenous Treatment of Severe Gram Negative Bacterial Infections
Expanded access may be provided for cefiderocol for qualified patients who have limited treatment options and are not eligible for a clinical trial.
- Trial name
- NCT03780140
- Testing
- Cefiderocol
- Sponsor
- Shionogi
Pneumococcal Infections, Pneumococcal Vaccines
Safety, Tolerability, and Immunogenicity of V114 in Healthy Infants (V114-029)
The purpose of this study is to evaluate the safety, tolerability, and immunogenicity of V114 in healthy infants. The primary hypotheses are that: 1) V114 is non-inferior to Prevnar 13™ for the 13 shared serotypes between V114…
- Trial name
- PNEU-PED (NCT03893448)
- Testing
- V114, Prevnar 13™, RotaTeq™
- Where
- 81 sites in United States, Puerto Rico and 2 more
- Volunteers
- 1,720 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Bacterial Vaginosis
The Efficacy and Safety Study of Clindamycin Palmitate Hydrochloride Dispersible Tablet Treatment of Bacterial Vaginosis
Randomized, double blind, positive drug parallel comparison, multi-centre clinical trial to assess the Efficacy and Safety of Clindamycin palmitate hydrochloride dispersible tablet for the treatment of bacterial vaginosis
- Trial name
- NCT03080740
- Testing
- Clindamycin palmitate hydrochloride dispersible tablet, Metronidazole Tablet
- Where
- China
- Volunteers
- 300 people
- Sponsor
- Guangzhou Yipinhong Pharmaceutical CO.,LTD
Fungal Infection
Pharmacokinetics, Safety, and Tolerability of Intravenous Posaconazole Solution Followed by Oral Posaconazole Suspension in Subjects at High Risk for Invasive Fungal Infections (P05520)
The purpose of this study is to collect pharmacokinetic (PK) information related to how well intravenous Posaconazole (POS IV), is distributed in the body and to determine the safety and tolerability of this new formulation.
- Trial name
- NCT01075984
- Testing
- Posaconazole, Dextrose 5% in water
- Volunteers
- 279 people
- Sponsor
- Merck Sharp & Dohme LLC
Screening for Syphilis Infections
Syph-Check Syphilis Antibody Point of Care (POC) Test
The study is designed to evaluate the performance of a rapid membrane test in a clinic or doctor's office setting to identify potential patients infected with syphilis and compare the results to currently licensed laboratory…
- Trial name
- SyphPoc (NCT00732355)
- Testing
- Syph-Check POC
- Where
- United States
- Volunteers
- 400 people, healthy volunteers welcome
- Sponsor
- Healthcare Providers Direct, Inc.
Tinea Pedis
Evaluate the Safety & Bioequivalence of a Generic Butenafine Cream & Lotrimin Ultra® & Compare Both to a Vehicle Control in Treatment of Interdigital Tinea Pedis
The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with…
- Trial name
- NCT01580878
- Testing
- Butenafine Hydrochloride Cream, 1%, Lotrimin Ultra®, Butenafine Vehicle
- Volunteers
- 707 people
- Sponsor
- Sun Pharmaceutical Industries, Inc.
Chronic Obstructive Pulmonary Disease (COPD)
Advanced Immunological Approach in COPD Exacerbation
Chronic obstructive pulmonary disease (COPD) are characterized by frequent relapses, often resulting from common bacterial infections. Enhancing the immune response in these patients may decrease the frequency of these relapses.
- Trial name
- AIACE (NCT02417649)
- Testing
- Ismigen
- Where
- 13 sites in Italy
- Volunteers
- 288 people
- Sponsor
- Lallemand Pharma AG
Infections
Evaluation of Ceftaroline Fosamil Versus a Comparator in Adult Subjects With Community-acquired Bacterial Pneumonia (CABP) With Risk for Methicillin-resistant Staphylococcus Aureus
The purpose of this study is to determine whether ceftaroline is effective and safe for the treatment of patients with Community-acquired Bacterial Pneumonia (CABP) at risk for infection due to Methicillin-resistant…
- Trial name
- NCT01645735
- Testing
- Ceftaroline fosamil, Ceftriaxone plus vancomycin
- Where
- 31 sites in United States, Georgia and 6 more
- Volunteers
- 49 people
- Sponsor
- Forest Laboratories
Clostridium Infections
Study of Nitazoxanide in the Treatment of Clostridium Difficile-associated Disease
The primary objective of the study is to demonstrate non-inferiority of nitazoxanide compared to vancomycin in resolving symptoms of Clostridium difficile-associated disease (CDAD).
- Trial name
- NCT00384527
- Testing
- Nitazoxanide, Vancomycin
- Where
- 10 sites in United States
- Volunteers
- 50 people
- Sponsor
- Romark Laboratories L.C.
Onychomycosis
Bioequivalency Study of Terbinafine Tablets Under Fasting Conditions
The objective of this study was the bioequivalence of a Roxane Laboratories' terbinafine tablets, 250 mg, to Lamisil® Tablets, 250 mg (Novartis Pharmaceutical Corporation.) under fasting conditions using a single-dose…
- Trial name
- NCT00602342
- Testing
- Terbinafine
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Roxane Laboratories
Crohn Disease, Ulcerative Colitis
The Evaluation of Injection Site Pain and Adherence in Patients Switching From a Low To High Concentration Adalimumab (AVT-02) Across Multiple Indications.
The purpose of the Phase IV study is to investigate the effects of both Volume and Citrate on Injection Site Pain (ISP), adherence, patient satisfaction, Quality of Life, and Disease Assessment in the Canadian Adalimumab Market.
- Conditions
- Crohn Disease, Ulcerative Colitis, Rheumatoid Arthritis, Ankylosing Spondylitis
- Trial name
- EASE PAIN (NCT05913817)
- Testing
- AVT02 (Alvotech Biosimilar to Adalimumab)
- Where
- Canada
- Volunteers
- 324 people
- Sponsor
- Jamp Pharma Corporation
Hidradenitis Suppurativa
Long Term Observational Study to Collect in a Real-world populatIon Data on the Treatment Pattern of secukinumAb in Adult Patients With Moderate to Severe Hidradenitis Suppurativa.
The purpose of this observational, prospective, non-interventional, multicenter, open-label, single arm study in Hidradenitis suppurativa (HS) is to assess the treatment pattern of secukinumab in a flexible dosing regimen and…
- Trial name
- ANIMA (NCT05921994)
- Testing
- secukinumab
- Where
- 80 sites in Germany
- Volunteers
- 436 people
- Sponsor
- Novartis Pharmaceuticals
Acellular Pertussis, Diphtheria
Safety and Immunogenicity of GSK's Tdap Vaccine (Boostrix) in Adults Aged 19 to 64 Years
GSK Biologicals' dTpa vaccine has recently been approved by the US Food and Drug Administration (FDA) for booster vaccination of adolescents aged 10 to 18 years.
- Conditions
- Acellular Pertussis, Diphtheria, Tetanus
- Trial name
- NCT00346073
- Testing
- Boostrix™, ADACEL®
- Where
- 42 sites in United States
- Volunteers
- 2,337 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Skin Diseases, Bacterial
Safety and Efficacy of CEM-102 Compared to Linezolid in Acute Bacterial Skin Infections
The purpose of this study is to determine the safety and efficacy of CEM-102 compared to Linezolid in the treatment of acute bacterial skin structure infections (ABSSIs).
- Trial name
- NCT00948142
- Testing
- CEM-102, Linezolid
- Where
- 16 sites in United States
- Volunteers
- 198 people
- Sponsor
- Arrevus Inc.
Pneumococcal Infections
A Study to Evaluate the Safety, Tolerability and Immunogenicity of V114 in Healthy Adults and Infants (V114-005)
This study is designed to assess the effect of different dose levels of pneumococcal polysaccharide and adjuvant on the safety and immunogenicity of V114 in healthy adults and infants.
- Trial name
- NCT02531373
- Testing
- V114 Medium Dose, V114 High Dose, V114 Medium Dose with Alternative Carrier Protein
- Volunteers
- 338 people, healthy volunteers welcome
- Sponsor
- Merck Sharp & Dohme LLC
Diphtheria, Tetanus
Sanofi Pasteur's Tdap Combined Vaccine as a Booster Versus Local DT Vaccine in Children or Versus Local Td Vaccine in Adolescents and Adults in China.
The aim of the study is to assess the immunogenicity and safety profile of ADACEL compared to local adsorbed diphtheria and tetanus combined vaccine (local DT or local Td vaccine in participants in China.
- Conditions
- Diphtheria, Tetanus, Pertussis
- Trial name
- NCT01993173
- Testing
- Tetanus Toxoid, Reduced Diphtheria Toxoid and Acellular Pertussis Vaccine Adsorbed Tdap (ADACEL), DT vaccine (Diphtheria and Tetanus Combined Vaccine, Adsorbed), Td vaccine (Diphtheria and Tetanus Combined Vaccine for Adults and Adolescents, Adsorbed)
- Where
- China
- Volunteers
- 1,440 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Staphylococcal Skin Infections, Diabetic Foot Infections
A Complicated Skin and Soft-tissue Infection Patient Registry
The purpose of this registry is to better understand (1) complicated skin and soft-tissue infections requiring hospitalization, and (2) clinical and economic outcomes in hospitalized patients receiving intravenous antibiotic…
- Conditions
- Staphylococcal Skin Infections, Diabetic Foot Infections, Surgical Wound Infection, Abscess
- Trial name
- NCT00737269
- Volunteers
- 1,081 people
- Sponsor
- Ortho-McNeil Janssen Scientific Affairs, LLC
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.